IMFINZI (durvalumab) - Non-small cell lung cancer (NSCLC)
Opinions on drugs -
Posted on
Dec 01 2025
Reason for request
Indication extension
Summary of opinion
Unfavourable opinion for reimbursement in the indication: “IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy as adjuvant treatment, is indicated for the treatment of adults with resectable NSCLC at high risk of recurrence and no EGFR mutations or ALK rearrangements”.
Clinical Benefit
| Insufficient |
The clinical benefit of IMFINZI 50 mg/mL (durvalumab) concentrate for solution for infusion is insufficient in the MA indication. |
Clinical Added Value
| Not applicable |
English version
Contact Us
Évaluation des médicaments
